Loading quotes...

Forecast

The analysts' average price target is €58.00 (+1.31%). The median is €60.09 (+4.96%).

Buy	12
Hold	16
Sell	1

News Go to news feed

Inspire Medical: management sees end of setbacks — growth expected to return in 2027

At the Wells Fargo conference, Inspire Medical said coding and reimbursement issues weighed on procedure volumes in 2026, but the company is operationally better positioned thanks to clearer Medicare rules and increasing acceptance of Inspire V. Second-quarter revenue fell about 7.5% but topped internal expectations and showed rising gross margins driven by product mix. With the $30 million efficiency program "Project Horizon", anticipated easing of reimbursement, and ongoing product development such as Inspire 6, management aims to return to revenue growth in 2027. » More on de.investing.com
Inspire Medical exceeds Q2 forecasts and raises full-year outlook

Inspire Medical delivered an adjusted earnings per share of $0.14 and revenue of $200.6 million in the second quarter, beating consensus estimates despite a 7.6% year-over-year revenue decline due to coding and reimbursement issues. The stock rose sharply after the results as management highlighted improving trends in prior authorizations and stronger international performance. The company launched the restructuring plan "Project Horizon", plans to free up $30 million annually for growth investments, and raised its 2026 full-year guidance, while still expecting a third-quarter revenue decline of 8–10% with sequential improvement. Financial metrics show solid liquidity ($415 million cash) and no debt, although risks remain in executing reimbursement and restructuring measures. » More on de.investing.com
Inspire Medical under pressure after downgrade over reimbursement uncertainty

Bank of America downgraded Inspire Medical from "Neutral" to "Underperform" and cut the price target from $53 to $39, saying a unified coding process and an official CPT code for Inspire V are not expected before early 2028. The company lowered its 2026 revenue outlook to $825–875 million and expects diluted EPS of $0.07–0.62, underscoring near-term revenue and earnings risks. CEO Tim Herbert said the company is working with stakeholders on solutions but expects persistent challenges through the end of 2026. The stock fell to new multi-year lows and is about 70% below last year’s level; the main recovery catalyst remains clarity on the reimbursement rules for Inspire V. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2008, Inspire Medical Systems has already paid €6.14 in dividends. The last payout was in January 2008.

Financials

In the last quarter, Inspire Medical Systems had revenue of €182.48M and net profit of -€21.54M

(EUR)	September 2026	YoY
Revenue	182.48M	4.61%
Gross profit	157.02M	4.39%
Net profit	-21.54M	354.46%
EBITDA	-17.54M	219.42%

Fundamentals

Metric	Value
Market capitalization	€1.66B
Number of shares	28.97M
52-week high/low	€131.86 - €34.89
Dividends	No
Beta	0.65
P/E ratio	18.38
PEG ratio	0.14
P/B ratio	2.24
P/S ratio	2.10

Company profile

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Name	Inspire Medical Systems
CEO	Timothy Herbert
Headquarters	Golden Valley, mn USA
Website	inspiresleep.com
Sector	Health Care
Industry	Health Care Technology
IPO	05/03/2018
Employees	1,333